Skip to main content

Lion s Revenues Decline Sharply in Q2 of FY05, Loss Narrows

NEW YORK, Nov. 4 (GenomeWeb News) - Lion Bioscience today reported a sharp revenue downturn for its second fiscal quarter, while the company cut its loss in half.

 

Lion booked €2.6 million ($3.4 million) in revenues for the quarter ended Sept. 30, down from €5 million ($6.4 million) during the same period last year.

 

The company did not state its R&D expenses for the quarter.

 

Lion's net loss for the quarter narrowed to €3.4 million from €6.5 million during the year-ago quarter. This reduction resulted from Lion's cost-cutting measures.

 

As of Sept. 30, Lion had €33.3 million in liquid assets.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.